Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct;10(10):1415-33.
doi: 10.1586/erv.11.120.

Respiratory syncytial virus vaccine development

Julia L Hurwitz  1
Affiliations
Review

Respiratory syncytial virus vaccine development

Julia L Hurwitz. Expert Rev Vaccines. 2011 Oct.

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract viral disease in infants and young children. Presently, there are no explicit recommendations for RSV treatment apart from supportive care. The virus is therefore responsible for an estimated 160,000 deaths per year worldwide. Despite half a century of dedicated research, there remains no licensed vaccine product. Herein are described past and current efforts to harness innate and adaptive immune potentials to combat RSV. A plethora of candidate vaccine products and strategies are reviewed. The development of a successful RSV vaccine may ultimately stem from attention to historical lessons, in concert with an integral partnering of immunology and virology research fields.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–1555. •• Defines the global burden of respiratory syncytial virus (RSV) infection and disease.

    1. Karron RA, Singleton RJ, Bulkow L, et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J. Infect. Dis. 1999;180:41–49. - PubMed
    1. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 2008;82:2040–2055. - PMC - PubMed
    1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 2009;360:588–598. - PMC - PubMed
    1. Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum. Vaccin. 2009;5:582–591. - PubMed

Websites

    1. Centers for Disease Control USA. Respiratory syncytial virus infection (RSV) www.cdc.gov/rsv.
    1. Medimmune discontinues development of motavizumab for RSV prophylaxis indication. http://pressroom.medimmune.com.
    1. The Robinson Library. Edward Jenner. www.robinsonlibrary.com/medicine/medicine/history/jenner.htm.
    1. Shaw C. Deconstructing RSV vaccine-enhanced disease in cotton rats. www.immunome.org/wp-content/uploads/2010/11/Shaw_Presentation_Vax_Ren_4.pdf.
    1. A randomized, double-blind, placebo-controlled study to evaluate viral shedding of MEDI-559 in healthy 1 to <24 month-old children. http://clinicaltrials.gov/ct2/show/NCT00767416.

Publication types

MeSH terms